{
  "id": "clinical#screening_cues_be521ad5",
  "content": "lowed by the name of the substance-induced anxiety disorder, followed\nAnxiety Disorder Due to Another Medical Condition 127\nby the specification of onset (i.e., onset during intoxication, onset dur-\ning withdrawal, onset during medication use). For example, in the case\nof anxiety symptoms occurring during withdrawal in a man with a se-\nvere lorazepam use disorder, the diagnosis is F13.280 severe loraze-\npam use disorder with lorazepam-induced anxiety disorder, with on-\nset during withdrawal. A separate diagnosis of the comorbid severe\nlorazepam use disorder is not given. If the substance-induced anxiety\ndisorder occurs without a comorbid substance use disorder (e.g., after\na one-time heavy use of the substance), no accompanying substance\nuse disorder is noted (e.g., F16.980 psilocybin-induced anxiety disor-\nder, with onset during intoxication). When more than one substance is\njudged to play a significant role in the development of anxiety symp-\ntoms, each should be listed separately (e.g., F15.280 severe methylphe-\nnidate use disorder with methylphenidate-induced anxiety disorder,\nwith onset during intoxication; F19.980 salbutamol-induced anxiety\ndisorder, with onset after medication use).\nAnxiety Disorder Due to Another Medical Condition\n293.84 (F06.4)\nA. Panic attacks or anxiety is predominant in the clinical picture.\nB. There is evidence from the history, physical examination, or lab-",
  "metadata": {
    "source": "DSM-5",
    "url": "https://psychiatry.org/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues lowed by the name of the substance-induced anxiety disorder, followed\nAnxiety Disorder Due to Another Medical Condition 127\nby the specification of onset (i.e., onset during intoxication, onset dur-\ning withdrawal, onset during medication use). For example, in the case\nof anxiety symptoms occurring during withdrawal in a man with a se-\nvere lorazepam use disorder, the diagnosis is F13.280 severe loraze-\npam use disorder with lorazepam-induced anxiety disorder, with on-\nset during withdrawal. A separate diagnosis of the comorbid severe\nlorazepam use disorder is not given. If the substance-induced anxiety\ndisorder occurs without a comorbid substance use disorder (e.g., after\na one-time heavy use of the substance), no accompanying substance\nuse disorder is noted (e.g., F16.980 psilocybin-induced anxiety disor-\nder, with onset during intoxication). When more than one substance is\njudged to play a significant role in the development of anxiety symp-\ntoms, each should be listed separately (e.g., F15.280 severe methylphe-\nnidate use disorder with methylphenidate-induced anxiety disorder,\nwith onset during intoxication; F19.980 salbutamol-induced anxiety\ndisorder, with onset after medication use).\nAnxiety Disorder Due to Another Medical Condition\n293.84 (F06.4)\nA. Panic attacks or anxiety is predominant in the clinical picture.\nB. There is evidence from the history, physical examination, or lab- Lowed by the name of the substance-induced lo âu disorder, followed\nlo âu disorder due to another medical condition 127\nby the specification of onset (i.e., onset during intoxication, onset dur-\ning withdrawal, onset dur..."
}